Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of MGTA-145 to Evaluate Mobilization and Collection of High-Quality Cells and Engraftment of the Cells after Transplant in Allogeneic and Autologous Transplant Settings Across Multiple Diseases

Next Previous
Trial Profile

A Phase 2 Study of MGTA-145 to Evaluate Mobilization and Collection of High-Quality Cells and Engraftment of the Cells after Transplant in Allogeneic and Autologous Transplant Settings Across Multiple Diseases

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EN 145 (Primary)
  • Indications Stem cell mobilisation
  • Focus Therapeutic Use
  • Sponsors Dianthus Therapeutics; Magenta Therapeutics

Most Recent Events

  • 11 Jan 2021 According to a Magenta Therapeutics media release, this trail is expected to begin within the next several weeks and initial data are expected in the second half of 2021.
  • 04 Nov 2020 According to a Magenta Therapeutics media release, this study is expected to begin by the end of 2020.
  • 11 Jun 2020 According to a Magenta Therapeutics media release, based on the results of the Phase 1 study and a productive end of Phase 1 meeting with the U.S. Food and Drug Administration (FDA), the company intends to initiate multiple Phase 2 trials of MGTA-145 to include both allogeneic and autologous transplant settings, with up to 150,000 patients eligible annually in the US and Europe

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top